Eli Lilly's Manjaro Surpasses Novo Nordisk's Wegovy in the UK

A significant change is underway in the UK weight loss medication market; Eli Lilly's Manjaro has begun to surpass Novo Nordisk's Wegovy among British customers paying for obesity treatments. Reports from online pharmacies indicate an increasing rate of preference for Manjaro over its competitor, demonstrating Eli Lilly's advancement against the European pharmaceutical company.

Manjaro is becoming increasingly appealing to consumers due to its higher efficacy shown in clinical trials conducted before the medication's approval. Data revealed that while Wegovy enables patients to lose an average of 15% of their body weight, Manjaro leads to nearly 23% weight loss, marking a noteworthy difference in outcomes.

Despite its growing popularity, Manjaro is not yet accessible through the UK's National Health Service (NHS). However, forecasts suggest it may become available through the NHS within the next year. In contrast, Wegovy has limited availability via the NHS, restricted to specialized obesity clinics and certain qualifying conditions.

Eli Lilly launched Manjaro in the UK in February, making it one of the first markets outside the United States where the drug was made available. Wegovy has been available in the UK market since 2023. It is estimated that about two-thirds of adults in the UK are overweight or obese, indicating a significant potential customer base for these obesity treatments.